Isunakinra is under clinical development by Buzzard Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Isunakinra’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Isunakinra overview
Isunakinra (EBI-005) is under development for the treatment of solid tumors, colorectal cancer, pancreatic cancer, triple-negative breast cancer (TNBC), anal cancer, prostate cancer and bile duct cancer (cholangiocarcinoma). The drug candidate is administered through subcutaneous route. It acts by targeting interleukin-1 (IL-1) receptor and is being developed based on AMP-Rx protein engineering platform.
The drug candidate was also under development for the treatment of moderate to severe allergic conjunctivitis, severe ocular allergy and dry eye disease, administered through ophthalmic route.
Buzzard Pharmaceuticals overview
Buzzard Pharmaceuticals is a drug oncology company that develops recombinant protein for cancer indications, and plans to tumor immuno-suppression by myeloid cells. It is headquartered in Stockholm, Sweden.
For a complete picture of Isunakinra’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
